Research programme: antibacterials - Pfizer/University of Auckland

Drug Profile

Research programme: antibacterials - Pfizer/University of Auckland

Alternative Names: PD 0305970; PNU 92560

Latest Information Update: 11 May 2007

Price : $50

At a glance

  • Originator Auckland Cancer Society Research Centre; Pfizer; University of Auckland
  • Class
  • Mechanism of Action DNA gyrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Bacterial infections

Most Recent Events

  • 30 Mar 2005 Data presented at the 229th American Chemical Society National Meeting (229th-ACS-2005) have been added to the Bacterial Infections antimicrobial activity section
  • 12 Nov 2004 Data presented at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2004) have been added to the Bacterial infections antimicrobial activity section ,
  • 10 Feb 2004 Research in Bacterial infections in New Zealand (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top